PATENT CLAIM ANALYSIS

Application Number: 15769308
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "339000"]

Abstract:
The present invention provides a pharmaceutical composition for use in treating acute myeloid leukemia (AML) and a method of treating AML in a patient in need thereof. The present invention also provides a method for predicting the sensitivity to the treatment in the patient using gene expression signature.

Claim (Index 21):
A method of predicting sensitivity to MDM2i treatment of AML in a patient suffering from AML, comprising measuring the expression levels of at least one, at least two, at least three, at least four or all of the 177 signature genes shown in  FIG. 1 , wherein the MDM2i is (3\u2032R,4\u2032S,5\u2032R)\u2014N-[(3R,6S)-6-Carbamoyltetrahydro-2H-pyran-3-yl]-6\u2033-chloro-4\u2032-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2\u2033-oxo-1\u2033,2\u2033-dihydrodispiro[cyclohexane-1,2\u2032-pyrrolidine-3\u2032,3\u2033-indole]-5\u2032-carboxamide or a salt thereof.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 91.0
- Lexical Diversity: 1.52941
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12438944', '13950881', '14560519', '14430635', '15566336']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7330655149302191
- 35 USC 102 Novelty (BERT): 0.5817572050799505
- Combined Prediction Score: 0.7179346839451922
- Mean Citation Score: 388.860316
- Max Citation Score: 521.67804
- Similarity Product: 368.93490281076913

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test